Appendix 4C - Quarterly report
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Pranas PBT434 shows potential as treatment in PD
- Pranas PBT434 Inhibits PD Protein & Brain Cell Death
- Pranas PBT2 Reduces Tau Related Cognitive Impairment
- Prana Provides Huntington Disease Trial Update
- Prana Provides Clinical Trials Safety and Progress Update
Later from Alterity Therapeutics
- Australian Government funds study into benefits of PBT2
- Key Patent for Parkinson`s Drug PBT434 Secured in USA
- Landmark Publication Endorses Prana`s Strategy
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics